PLAUR and glioblastoma: First, our binding moiety has previously been tested as a uPAR targeting PET probe (68Ga-NOTA-AE105) in multiple cancer types 14, 34, 35 (NCT03278275, NCT02755675, NCT03307460, NCT02960724, NCT02805608, NCT02964988, NCT02681640, NCT02965001) including an ongoing phase II trial in patients with GBM (NCT02945826).